Efficacy and safety of pegylated interferon-α2b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study

International Journal of Infectious Diseases ◽

10.1016/j.ijid.2021.08.044 ◽

2021 ◽

Vol 111 ◽

pp. 281-287

Author(s):

Shashi Bhushan B L ◽

Sunil Wanve ◽

Parshottam Koradia ◽

Vinay Bhomia ◽

Pravin Soni ◽

...

Keyword(s):

Pegylated Interferon ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Interferon Α2b

Download Full-text

THE EFFICACY AND SAFETY OF ALIROCUMAB IN CHILDREN AND ADOLESCENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH): PHASE 3, MULTINATIONAL OPEN-LABEL STUDY

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(21)01800-3 ◽

2021 ◽

Vol 77 (18) ◽

pp. 441

Author(s):

Eric Bruckert ◽

Sonia Caprio ◽

Albert Wiegman ◽

Min-Ji Charng ◽

Cézar A. Zárate-Morales ◽

...

Keyword(s):

Children And Adolescents ◽

Familial Hypercholesterolemia ◽

Efficacy And Safety ◽

Homozygous Familial Hypercholesterolemia ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study

Download Full-text

Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study

The Journal of Dermatology ◽

10.1111/1346-8138.14294 ◽

2018 ◽

Vol 45 (5) ◽

pp. 529-539 ◽

Cited By ~ 26

Author(s):

Shigetoshi Sano ◽

Hiroshi Kubo ◽

Hitomi Morishima ◽

Ryosuke Goto ◽

Richuan Zheng ◽

...

Keyword(s):

Monoclonal Antibody ◽

Japanese Patients ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Generalized Pustular Psoriasis ◽

Erythrodermic Psoriasis ◽

Interleukin 23

Download Full-text

Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN)

BMC Endocrine Disorders ◽

10.1186/s12902-020-0524-7 ◽

2020 ◽

Vol 20 (1) ◽

Author(s):

Zhenmei An ◽

◽

Ting Lei ◽

Lian Duan ◽

Pei Hu ◽

...

Keyword(s):

Chinese Patients ◽

Prolonged Release ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Active Acromegaly ◽

Lanreotide Autogel

Download Full-text

Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study

Hepatology International ◽

10.1007/s12072-017-9788-z ◽

2017 ◽

Vol 11 (2) ◽

pp. 188-198 ◽

Cited By ~ 2

Author(s):

Mark S. Sulkowski ◽

Walford J. Fessel ◽

Adriano Lazzarin ◽

Juan Berenguer ◽

Natalia Zakharova ◽

...

Keyword(s):

Pegylated Interferon ◽

Interferon Alfa ◽

Phase Iii ◽

Efficacy And Safety ◽

Genotype 1 ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Pegylated Interferon Alfa ◽

Hcv Genotype 1

Download Full-text

Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study

International Journal of Infectious Diseases ◽

10.1016/j.ijid.2021.03.015 ◽

2021 ◽

Vol 105 ◽

pp. 516-521

Author(s):

Anuja Pandit ◽

Nirav Bhalani ◽

B.L. Shashi Bhushan ◽

Parshottam Koradia ◽

Shweta Gargiya ◽

...

Keyword(s):

Phase Ii ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Efficacy And Safety ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Randomized Controlled ◽

Pegylated Interferon Alfa

Download Full-text

Corrigendum to “Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study” [International Journal of Infectious Diseases, Volume 105, April 2021, Pages 516-521]

International Journal of Infectious Diseases ◽

10.1016/j.ijid.2021.06.030 ◽

2021 ◽

Author(s):

Anuja Pandit ◽

Nirav Bhalani ◽

B.L. Shashi Bhushan ◽

Parshottam Koradia ◽

Shweta Gargiya ◽

...

Keyword(s):

Infectious Diseases ◽

Phase Ii ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Efficacy And Safety ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Randomized Controlled ◽

Pegylated Interferon Alfa

Download Full-text

Abstract CT136: STELLAR: A phase 3, randomized, open-label study to evaluate the efficacy and safety of eflornithine with lomustine compared to lomustine alone in patients with anaplastic astrocytoma that progress/recur after irradiation and adjuvant temozolomide chemotherapy

10.1158/1538-7445.am2017-ct136 ◽

2017 ◽

Author(s):

Victor A. Levin ◽

Scott Cruickshank

Keyword(s):

Anaplastic Astrocytoma ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Adjuvant Temozolomide ◽

Temozolomide Chemotherapy

Download Full-text

FRI0543 EFFICACY AND SAFETY OF INTRAVENOUS GOLIMUMAB IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS: RESULTS FROM A PHASE 3 OPEN-LABEL STUDY

10.1136/annrheumdis-2019-eular.333 ◽

2019 ◽

Author(s):

Nicolino Ruperto ◽

Alberto Spindler ◽

Cesar Francisco Pacheco Tena ◽

Ingrid Louw ◽

Gabriel Vega Cornejo ◽

...

Keyword(s):

Juvenile Idiopathic Arthritis ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study

Download Full-text

LP14 : A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: Optimist-1

Journal of Hepatology ◽

10.1016/s0168-8278(15)30168-9 ◽

2015 ◽

Vol 62 ◽

pp. S270 ◽

Cited By ~ 44

Author(s):

P. Kwo ◽

N. Gitlin ◽

R. Nahass ◽

D. Bernstein ◽

S. Rojter ◽

...

Keyword(s):

Efficacy And Safety ◽

Genotype 1 ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Hcv Genotype ◽

Treatment Naïve ◽

Hcv Genotype 1 ◽

Chronic Hcv

Download Full-text

Increase in Incidence of Hepatocellular Carcinoma in Chronic Hepatitis C Chinese After Sustained Virologic Response with Direct Acting Antiviral Agents as Compared to Pegylated Interferon Plus Ribavirin Therapy: A Prospective Open-Label Study

SSRN Electronic Journal ◽

10.2139/ssrn.3393711 ◽

2019 ◽

Author(s):

Dong Ji ◽

Guo-feng Chen ◽

Ping Han ◽

Cheng Wang ◽

Qing Shao ◽

...

Keyword(s):

Antiviral Agents ◽

Pegylated Interferon ◽

Virologic Response ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Direct Acting Antiviral ◽

Pegylated Interferon Plus Ribavirin ◽

Direct Acting ◽

Direct Acting Antiviral Agents

Download Full-text